missing translation for 'onlineSavingsMsg'
Learn More
Learn More
R&D Systems™ Recombinant Human VEGFR2/KDR Fc Chimera Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
Marke: R&D Systems™ 357-KD-050
428.50 CHF gültig bis 2024-12-16
Benutzen Sie den Promotions-Code "21630" um Ihren Promotions-Preis zu erhalten.
Dieser Artikel kann nicht zurückgegeben werden.
Rückgaberichtlinie anzeigen
Beschreibung
The Recombinant Human VEGFR2/KDR Fc Chimera Protein is derived from NS0. The Recombinant Human VEGFR2/KDR Fc Chimera Protein has been validated for the following applications: Bioactivity.Spezifikation
Lyophilized from a 0.2μm filtered solution in PBS with BSA as a carrier protein. | |
110 kDa (monomer) | |
50 μg | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution. | |
CD309, CD309 antigen, EC 2.7.10, EC 2.7.10.1, Fetal liver kinase 1, fetal liver kinase-1, Flk1, Flk-1, FLK1tyrosine kinase growth factor receptor, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), KRD1, Ly73, Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, vascular endothelial growth factor receptor 2, VEGF R2, VEGFR, VEGFR2, VEGFR-2 | |
Recombinant |
3791 | |
VEGFR2/KDR/Flk-1 | |
Mouse myeloma cell line,NS0-derived human VEGFR2/KDR/Flk-1 protein, (N-terminus) Human VEGFR2 (Ala20-Glu764) Accession &Num; AAC16450 IEGRMD Human IgG1 (Pro100-Lys330) 6-His tag (C-terminus) | |
Disulfide-linked homodimer | |
Unconjugated | |
90%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
Berichtigung von Produktinhalten
Bitte geben Sie uns Ihr Feedback zu den Produktinhalten, indem Sie das folgende Formular ausfüllen.
Name des Produkts
Haben Sie Verbesserungsvorschläge?Übermitteln Sie eine inhaltliche Korrektur